Structure Therapeutics Inc. (GPCR) — SEC Filings
Structure Therapeutics Inc. (GPCR) — 39 SEC filings. Latest: 8-K (Apr 15, 2026). Includes 17 8-K, 8 SC 13G/A, 5 10-Q.
View Structure Therapeutics Inc. on SEC EDGAR
Overview
Structure Therapeutics Inc. (GPCR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 15, 2026: Structure Therapeutics Inc. filed an 8-K on April 15, 2026, reporting on the departure of a director or officer, compensatory arrangements, and Regulation FD disclosures. The filing also includes financial statements and exhibits.
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 3 bullish, 35 neutral, 1 mixed. The dominant filing sentiment for Structure Therapeutics Inc. is neutral.
Filing Type Overview
Structure Therapeutics Inc. (GPCR) has filed 17 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G, 8 SC 13G/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of GPCR's 25 recent filings, 1 were flagged as high-risk, 5 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | Not Disclosed |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Dr. Jian-Hua Xu
- Dr. Xiaojun Tang
- Jianmin Feng
- Class I director
- Abigail P. Johnson
Industry Context
Structure Therapeutics Inc. operates in the highly competitive biotechnology sector, focusing on the development of novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies in this space often rely on external financing and strategic partnerships to advance their pipelines.
Top Tags
corporate-actions (8) · financial-reporting (7) · institutional-ownership (4) · Biotechnology (3) · 10-Q (3) · financials (3) · amendment (3) · corporate-governance (2) · disclosure (2) · pharmaceuticals (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating clinical-stage status |
| Proceeds from Follow-On Offering | $172.7M | significantly bolstered capital on June 7, 2024 |
| Proceeds from Overallotment Option | $17.186M | additional capital raised on June 7, 2024 |
| American Depositary Shares (ADSs) | 17,270,000 | issued in the June 2024 follow-on offering |
| Total Assets | 172,610,000 | As of March 31, 2025 |
| Total Liabilities | 171,860,000 | As of March 31, 2025 |
| Cash and Cash Equivalents | $171.8M | As of September 30, 2024, indicating available liquidity. |
| CMO Salary | $475,000 | Annual base salary for new Chief Medical Officer, Dr. Jian-Hua Xu. |
| CDO Salary | $450,000 | Annual base salary for new Chief Development Officer, Dr. Xiaojun Tang. |
| Cash and cash equivalents | $171.6B | Indicates financial resources available for operations and R&D. |
| Total assets | $139.2M | Represents the company's overall financial standing. |
| Acquisition Value | $2.8B | Total amount D.E. Shaw & Co. is paying for Structure Therapeutics. |
| Reporting Period End Date | 2024-03-31 | The 10-Q covers the period ending March 31, 2024. |
| Filing Date | 2024-05-09 | The 10-Q was filed on May 9, 2024. |
| Name Change Date | 2021-10-19 | Date when ShouTi Inc. changed its name to Structure Therapeutics Inc. |
Forward-Looking Statements
- {"claim":"The reporting entities will maintain a passive investment approach in Structure Therapeutics Inc.","entity":"FIL Limited, Pandanus Partners, L.P., Pandanus Associates, Inc.","targetDate":"Ongoing","confidence":"high"}
- {"claim":"FMR LLC will maintain its significant passive stake in Structure Therapeutics Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"Structure Therapeutics Inc.'s stock price will experience increased stability due to institutional backing.","entity":"Structure Therapeutics Inc.","targetDate":"2024-08-09","confidence":"medium"}
- {"claim":"Other institutional investors may increase their positions in Structure Therapeutics Inc.","entity":"Structure Therapeutics Inc.","targetDate":"Next 6-12 months","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Structure Therapeutics Inc. (GPCR)?
Structure Therapeutics Inc. has 39 recent SEC filings from Feb 2024 to Apr 2026, including 17 8-K, 8 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GPCR filings?
Across 39 filings, the sentiment breakdown is: 3 bullish, 35 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Structure Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Structure Therapeutics Inc. (GPCR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Structure Therapeutics Inc.?
Key financial highlights from Structure Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GPCR?
The investment thesis for GPCR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Structure Therapeutics Inc.?
Key executives identified across Structure Therapeutics Inc.'s filings include Dr. Jian-Hua Xu, Dr. Xiaojun Tang, Jianmin Feng, Class I director, Abigail P. Johnson.
What are the main risk factors for Structure Therapeutics Inc. stock?
Of GPCR's 25 assessed filings, 1 were flagged high-risk, 5 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Structure Therapeutics Inc.?
Recent forward-looking statements from Structure Therapeutics Inc. include guidance on {"claim":"The reporting entities will maintain a passive investment approach in Structure Therapeutics Inc.","entity":"F and 3 other predictions.